Givaudan

The Indian competition commission CCI has been investigating Givaudan over alleged price‑fixing in the fragrance industry since 2024. An investigative report was delivered to the firms in February but withdrawn in July because trade secrets were not sufficiently redacted; the authority must revise the report, which could further delay the proceedings. Givaudan did not comment, and the stock reacted only slightly weaker. » More on finanzen.net

Givaudan increased organic growth in the second quarter; for the first half organic sales rose 3.6% to 3.8 billion francs, but nominally there was a 1.7% decline due to negative currency effects. Adjusted EBITDA fell 5% in the first half to 923 million francs and the margin dropped to 24.3%; net profit fell by one fifth to 475 million francs. The company emphasizes balanced growth across regions and customer groups and price increases to offset higher raw material costs, but cited one-off charges of 103 million francs from settlement payments, provisions, restructuring and investigations as a drag; the stock was trading about 7% lower in the afternoon. » More on finanzen.net

Givaudan accelerated organic growth in the second quarter; for the first half organic sales rose 3.6% to 3.8 billion francs, but nominally fell 1.7% due to negative currency effects. Adjusted EBITDA decreased 5% in the half-year to 923 million francs, the margin fell to 24.3%, and net income declined by about 20% to 475 million francs. The company cited one-off items of 103 million francs (settlement payments, provisions, restructuring, costs related to competition investigations) as a drag; the stock fell in premarket trading and at times lost around 4.8% on the SIX. » More on finanzen.net